629 related articles for article (PubMed ID: 24252258)
1. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
[TBL] [Abstract][Full Text] [Related]
2. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.
Ellis KA; Bush AI; Darby D; De Fazio D; Foster J; Hudson P; Lautenschlager NT; Lenzo N; Martins RN; Maruff P; Masters C; Milner A; Pike K; Rowe C; Savage G; Szoeke C; Taddei K; Villemagne V; Woodward M; Ames D;
Int Psychogeriatr; 2009 Aug; 21(4):672-87. PubMed ID: 19470201
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age.
Buckley R; Saling MM; Ames D; Rowe CC; Lautenschlager NT; Macaulay SL; Martins RN; Masters CL; O'Meara T; Savage G; Szoeke C; Villemagne VL; Ellis KA;
Int Psychogeriatr; 2013 Aug; 25(8):1307-15. PubMed ID: 23693133
[TBL] [Abstract][Full Text] [Related]
4. Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS).
Lim YY; Jaeger J; Harrington K; Ashwood T; Ellis KA; Stöffler A; Szoeke C; Lachovitzki R; Martins RN; Villemagne VL; Bush A; Masters CL; Rowe CC; Ames D; Darby D; Maruff P
Arch Clin Neuropsychol; 2013 Jun; 28(4):320-30. PubMed ID: 23552802
[TBL] [Abstract][Full Text] [Related]
5. Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up.
Burnham SC; Rowe CC; Baker D; Bush AI; Doecke JD; Faux NG; Laws SM; Martins RN; Maruff P; Macaulay SL; Rainey-Smith S; Savage G; Ames D; Masters CL; Wilson W; Villemagne VL
Neurology; 2016 Sep; 87(11):1093-101. PubMed ID: 27534714
[TBL] [Abstract][Full Text] [Related]
6. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
7. Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.
Rowe CC; Bourgeat P; Ellis KA; Brown B; Lim YY; Mulligan R; Jones G; Maruff P; Woodward M; Price R; Robins P; Tochon-Danguy H; O'Keefe G; Pike KE; Yates P; Szoeke C; Salvado O; Macaulay SL; O'Meara T; Head R; Cobiac L; Savage G; Martins R; Masters CL; Ames D; Villemagne VL
Ann Neurol; 2013 Dec; 74(6):905-13. PubMed ID: 24448836
[TBL] [Abstract][Full Text] [Related]
8. Personal memory function in mild cognitive impairment and subjective memory complaints: results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing.
Buckley RF; Saling MM; Irish M; Ames D; Rowe CC; Lautenschlager NT; Maruff P; Macaulay SL; Martins RN; Masters CL; Rainey-Smith SR; Rembach A; Savage G; Szoeke C; Ellis KA
J Alzheimers Dis; 2014; 40(3):551-61. PubMed ID: 24496075
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
10. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
Dukart J; Sambataro F; Bertolino A
J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
[TBL] [Abstract][Full Text] [Related]
11. Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study.
Faux NG; Ellis KA; Porter L; Fowler CJ; Laws SM; Martins RN; Pertile KK; Rembach A; Rowe CC; Rumble RL; Szoeke C; Taddei K; Taddei T; Trounson BO; Villemagne VL; Ward V; Ames D; Masters CL; Bush AI
J Alzheimers Dis; 2011; 27(4):909-22. PubMed ID: 21891867
[TBL] [Abstract][Full Text] [Related]
12. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
13. Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative.
Ellis KA; Rowe CC; Villemagne VL; Martins RN; Masters CL; Salvado O; Szoeke C; Ames D;
Alzheimers Dement; 2010 May; 6(3):291-6. PubMed ID: 20451879
[TBL] [Abstract][Full Text] [Related]
14. Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Lim YY; Ellis KA; Harrington K; Ames D; Martins RN; Masters CL; Rowe C; Savage G; Szoeke C; Darby D; Maruff P; The Aibl Research Group
J Clin Exp Neuropsychol; 2012; 34(4):345-58. PubMed ID: 22248010
[TBL] [Abstract][Full Text] [Related]
15. Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years.
Bradfield NI; Ellis KA; Savage G; Maruff P; Burnham S; Darby D; Lautenschlager NT; Martins RN; Masters CL; Rainey-Smith SR; Robertson J; Rowe C; Woodward M; Ames D
Alzheimer Dis Assoc Disord; 2018; 32(3):190-196. PubMed ID: 29561277
[TBL] [Abstract][Full Text] [Related]
16. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
Rembach A; Watt AD; Wilson WJ; Villemagne VL; Burnham SC; Ellis KA; Maruff P; Ames D; Rowe CC; Macaulay SL; Bush AI; Martins RN; Masters CL; Doecke JD;
J Alzheimers Dis; 2014; 40(1):95-104. PubMed ID: 24334723
[TBL] [Abstract][Full Text] [Related]
17. Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing.
Hare DJ; Faux NG; Roberts BR; Volitakis I; Martins RN; Bush AI
Metallomics; 2016 Jun; 8(6):628-32. PubMed ID: 26962965
[TBL] [Abstract][Full Text] [Related]
18. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
[TBL] [Abstract][Full Text] [Related]
19. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
20. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease.
Julayanont P; Brousseau M; Chertkow H; Phillips N; Nasreddine ZS
J Am Geriatr Soc; 2014 Apr; 62(4):679-84. PubMed ID: 24635004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
